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ABSTRACT
Sex steroids are important regulators of bone turnover, but the mechanisms of their effects on bone remain unclear. Sclerostin is
an inhibitor of Wnt signaling, and circulating estrogen (E) levels are inversely associated with sclerostin levels in postmenopausal
women. To directly test for sex steroid regulation of sclerostin levels, we examined effects of E treatment of postmenopausal
women or selective withdrawal of E versus testosterone (T) in elderly men on circulating sclerostin levels. E treatment of
postmenopausal women (n¼17) for 4 weeks led to a 27% decrease in serum sclerostin levels [versus þ1% in controls (n¼18),
p<.001].Similarly,in59elderlymen,weeliminatedendogenousEandTproductionandstudiedthemunderconditionsofphysiologicT
and E replacement, and then following withdrawal of T or E, we found that E, but not T, prevented increases in sclerostin levels following
induction of sex steroid deficiency. In both sexes, changes in sclerostin levels correlated with changes in bone-resorption, but not bone-
formation, markers (r¼0.62, p<.001, and r¼0.33, p¼.009, for correlations with changes in serum C-terminal telopeptide of type 1
collagen in the women and men, respectively). Our studies thus establish that in humans, circulating sclerostin levels are reduced by
E but not by T. Moreover, consistent with recent data indicating important effects of Wnts on osteoclastic cells, our findings
suggest that in humans, changes in sclerostin production may contribute to effects of E on bone resorption.  2011 American Society
for Bone and Mineral Research.
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Introduction
B
oth estrogen (E) and testosterone (T) are critical regulators of
bone turnover, but the precise mechanisms by which these
sex steroids have their effects on bone remain unclear. In
women, E clearly reduces bone resorption,
(1) and this effect is
mediated by an inhibition of osteoclast development and
activity, as well as increased osteoclast apoptosis (for review, see
ref. 2). Effects of E on bone formation have been more difficult to
define. E deficiency is associated with an increase in bone
remodeling,
(3) and the associated increase in bone resorption is
accompanied by a coupled increase in bone formation at the
tissue level.
(2) However, at each basic multicellular unit (BMU)
there remains a gap between bone resorption and bone
formation, with formation unable to keep up with resorption,
resulting in a net loss of bone.
(2) By inference, therefore, sex
steroid deficiency is associated with a defect in bone formation.
Consistent with this, several studies now demonstrate that acute
(3to 4weeks)E withdrawal
(4) ortreatment
(5) results ina decrease
and increase, respectively, in bone-formation markers, reflecting
the underlying effects of E in maintaining bone formation at the
cellular level. However, chronic E treatment of postmenopausal
women is associated with reduced bone-resorption markers,
leading, owing to the ‘‘coupling’’ of bone resorption and bone
formation, to a reduction in bone-formation markers.
(1,5) Studies
in rats also have found that histologic bone-formation rates
decrease early (at 5 days) following ovariectomy, but owing to
the coupling with the increase in bone resorption, bone-
formation rates are elevated 2 to 3 weeks following ovariect-
omy.
(6) Thus, at the cellular level, E is important for the
maintenance of bone formation in part due to a reduction in
osteoblast apoptosis.
(7)
Studies in men also have demonstrated a critical role for E in
suppressing bone resorption and in maintaining bone forma-
tion.
(8–10) Effects of E appear to be dominant over those of T, at
least for bone resorption.
(8) T effects on maintaining bone
formation in humans appear to vary depending on the bone-
formation marker used. We previously found that decreases in
serum N-terminal propeptide of type 1 collagen (P1NP) levels
following acute (3 weeks) E and T deficiency in men were
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27prevented by E but not T, whereas both E and T were able to
prevent decreases in serum osteocalcin (OCN) levels.
(8)
The identification of the Wnt/b-catenin signaling pathway as a
major regulator of bone mass
(11,12) has led to considerable
interest in potential crosstalk between this pathway and sex
steroid signaling.
(13) A major regulator of Wnt signaling is
sclerostin, which is a secreted Wnt antagonist produced by
osteocytes that regulates bone mass by binding to low-density
lipoprotein receptor-related protein (LRP)5 and LRP6 to inhibit
the canonical Wnt/b-catenin signaling pathway. The biologic
importance of sclerostin in regulating bone mass in humans is
highlighted by two genetic disorders associated with markedly
increased bone mass: sclerosteosis and van Buchem disease.
(14–
17) These findings, combined with the demonstration that
sclerostin-deficient mice have increased bone mass,
(18) have led
to the development of antisclerostin neutralizing antibodies as a
novel anabolic treatment for osteoporosis.
(19)
The recent development of immunoassays for sclerostin led to
the observation by Mirza and colleagues
(20) that postmenopau-
sal women had higher serum sclerostin levels than premeno-
pausal women, and in postmenopausal women, serum sclerostin
levelswereinverselyassociatedwiththecirculatingfreeestradiol
(E2) index. These findings suggest that E may regulate sclerostin
production; however, correlation does not prove causality, so in
this study we tested the possible regulation by E of circulating
sclerostin levels in women and in men. In addition, in the men,
we also compared effects of E versus T on serum sclerostin levels
and in both sexes related changes in sclerostin levels following
hormonal manipulations to changes in bone turnover markers.
Methods
Study subjects and experimental protocol
Study A: Women
Serum samples for the sclerostin measurements were from a
previous study from our group.
(21) Briefly, 34 early postmeno-
pausal women aged 40 to 65 years were randomized into an
open-label, controlled study to receive E treatment or no
treatment for 4 weeks. Menopausal status was defined by the
absence ofmensesfor morethan1 year in a woman over50years
of age, and in women with previous hysterectomy or those under
50 years of age, an elevated value for serum follicle-stimulating
hormone (FSH) was required.All women werehealthy and had no
clinically significant abnormalities in laboratory values and no
diseases known to affect bone metabolism, and they were not
taking any drug known to affect bone turnover. All subjects
provided full informed consent, and the study was approved by
the Mayo Clinic Institutional Review Board. Details regarding
ensuring vitamin D sufficiency in the study subjects have been
described previously.
(21) Subjects randomized to E treatment
(n¼17)received17b-estradiol(17b-E2,10 0mg/day)bycutaneous
patches (Vivelle, Novartis, East Hanover, NJ, USA) that were
changed every 3 to 4 days for 4 weeks. Fasting (8 a.m.) serum
samplesweredrawnatbaselineandat28daysoftreatment(orno
treatment in the control group). Serum samples were frozen and
stored at  808C, and only previously unthawed samples were
used in all analyses in this study.
Study B: Men
The samples for this study were derived from a previously
published study on the regulation of bone turnover by sex
steroids in men.
(10) Briefly, 59 elderly men aged 50 to 80 years
were recruited for the study. As for study A, all men were healthy
and had no clinically significant abnormalities in laboratory
values, no diseases known to affect bone metabolism, and were
not taking any drug known to affect bone turnover. All subjects
provided full informed consent, and the study was approved by
the Mayo Clinic Institutional Review Board. Details regarding
ensuring vitamin D sufficiency in these study subjects also have
been described previously.
(10)
At the time of entry into the study, the subjects were
administered a long-acting gonadotropin-releasing hormone
(GnRH) agonist [leuprolide acetate (Lupron-Depot), TAP Phar-
maceuticals, Deerfield, IL, USA], 7.5mg intramuscularly, to
suppress endogenous T and E production. They also were
started on the aromatase inhibitor [letrozole (Femara), Novartis],
2.5mg/day. Physiologic T and E2 levels were maintained by
starting the subjects on a T gel (AndroGel, Solvay Pharmaceu-
ticals, Marietta, GA, USA), 5g/day (delivering 5mg/day of T), as
well as an E2 patch (VivelleDot, Novartis), 37.5 mg/day. After
3 weeks following GnRH agonist administration and while
maintaining letrozole, T, and E2 treatment, the subjects were
admitted to the Mayo Clinical Research Unit (CRU) for their
baseline visit. After an overnight fast, serum samples were drawn
at 8 a.m. for the study assays. Following the baseline studies,
the subjects were randomized into one of four groups: group A
(–T, –E; n¼15) discontinued both T and E replacement, group B
(–T,þE;n¼15)discontinued theTgelbutcontinuedtheEpatch,
group C (þT, –E; n¼15) discontinued the E patch but continued
the T gel, and Group D (þT, þE, n¼14) continued both the T gel
and the E patch. All subjects received a second dose of the GnRH
agonist, and all subjects continued letrozole treatment through-
out the study period. Three weeks following randomization, the
subjects were readmitted to the CRU for their final visit, and
repeat fasting (8 a.m.) blood samples were obtained. As for study
A, serum samples were frozen and stored at –808C, and only
previously unthawed samples were used in all analyses in this
study.
Hormonal and biochemical assays
Serum calcium and phosphorus concentrations were measured
by an automated photometric assay [interassay coefficient of
variation (CV)<10%; Roche Diagnostics, Madison, WI, USA].
Serum creatinine was measured using an automated enzymatic
colorimetric assay (interassay CV<10%; Roche Diagnostics).
Serum 25-hydroxyvitamin D [25(OH)D] was measured using
tandem mass spectroscopy (interassay CV<7%; API 5000,
Applied Biosystems-MDS Sciex, Carlsbad, CA, USA). Serum
P1NP was measured by radioimmunassay [interassay
CV<10%; Immunodiagnostic Systems (IDS, Scotsdale, AZ,
USA)], and serum osteocalcin (OCN) was measured using a
two-site immunoradiometric assay (interassay CV<8%; CIS-US,
Bedford, MA, USA). Serum C-terminal telopeptide of type I
collagen (CTX) was measured by ELISA (interassay CV<8%; IDS),
and serum tartrate-resistant acid phosphatase isoform type 5b
28 Journal of Bone and Mineral Research MO ¨DDER ET AL.(TRACP5b) also was measured by ELISA (interassay CV<14%;
IDS), as was serum osteoprotegerin (OPG; interassay CV<8%;
ALPCO Immunoassays, Salem, NH, USA).
To measure serum sclerostin levels, we used two different
immunoassays in study A, an in-house assay and a commercial
assay. Because we observed similar changes with the two assays,
only the commercial assay was used in study B. For the in-house
assay, we used an ELISA developed in our laboratory. A
biotinylated goat antihuman sclerostin antibody (R&D Systems,
Minneapolis, MN, USA) was added to streptavidin-coated plates
followed by the samples and standards (recombinant human
sclerostin,R&DSystems).Aftera3-hourincubation,amonoclonal
antihuman sclerostin antibody (R&D Systems) was added.
Following a 1-hour incubation, antimouse IgG–horseradish
peroxidase was added for 30minutes. The plate was washed
forafinaltime,substratewasaddedfor30minutes,andtheplate
was read at 450/620. The interassay CV was 8%, and the lower
limit of detection was 100pg/mL. For the commercial assay, we
used a recently available quantitative sandwich ELISA obtained
from ALPCO (developed by Biomedica, Vienna, Austria).
(22)
The interassay CV was 4%, and the lower limit of detection was
86pg/mL.
Statistical analysis
For study A, the comparisons between the control and E-treated
women were made using two-sample, two-sided t tests. For
study B, as described previously,
(8,10) the primary method of
analysis to dissect out effects of E versus T on the various
parameters took advantage of the factorial design. Thus we used
a two-factor ANOVA model to compare the changes in the
variables in the þE (groups B and D) versus–E (groups A and C)
and þT (groupsC and D) versus–T (groups A and C) groups
(essentially pooling the two –E and two þE groups for
comparison and similarly for the –T and þT groups). For
both studies, the relationships between various variables of
interest were defined using the Pearson correlation. A one-
sample, two-sided t test was used to assess percent changes
from baseline for variables where we had baseline and final
measurements. Results were considered significant at the
p<.05 level.
Results
Baseline parameters in study subjects
Table 1 shows the baseline anthropometric and biochemical
variables in the study subjects. As is evident, for both studies, the
subjects in the various groups were well matched for all these
variables. Similarly, bone turnover markers and serum sclerostin
levels (measured using boththe in-house and commercial assays
in the women but only the commercial assay in the men) were
similar across all study groups at baseline (Table 2).
Table 1. Baseline Anthropometric and Biochemical Parameters in the Study Subjects
Study A: Women
Group Control E p Value
a
N 18 17
Age, years 54 15 4  1 .902
Height, m 1.67 0.01 1.63 0.02 .047
Weight, kg 76.2 3.7 74.7 3.0 .762
Body mass index (BMI), kg/m
2 27.4 1.3 28.3 1.3 .592
Serum parameters
Ca, mg/dL 9.7 0.1 9.7 0.1 .692
Phosphorus, mg/dL 3.7 0.1 3.9 0.1 .335
Cr, mg/dL 1.0 0.03 0.9 0.03 .204
25(OH)D, ng/mL 31.3 2.1 33.5 1.6 .425
Study B: Men
Group –T, –E –T, þE þT, –E þT, þE p Value
b
N 15 15 15 14
Age, years 66 36 6  27 0  16 6  3 0.603
Height, m 1.76 0.01 1.77 0.03 1.79 0.02 1.79 0.02 0.701
Weight, kg 87.3 2.9 86.7 3.4 88.4 2.3 90.0 3.3 0.879
BMI, kg/m
2 28.1 1.0 27.7 0.9 27.7 0.7 28.1 0.9 .959
Serum parameters
Ca, mg/dL 9.4 0.1 9.6 0.1 9.4 0.1 9.4 0.1 .318
Phosphorous, mg/dL 3.4 0.1 3.5 0.1 3.3 0.1 3.1 0.1 .128
Cr, mg/dL 1.1 0.03 1.2 0.04 1.1 0.03 1.2 0.03 .189
25(OH)D, ng/mL 31.1 1.6 28.3 2.2 32.1 2.5 32.2 2.5 .579
aFor comparison of control and estrogen groups.
bFor comparison of all four groups by ANOVA.
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levels following hormonal manipulations
Table 3 shows the percent changes from baseline in bone
turnover markers in the study subjects. As has been described
before for the early effects of E treatment on bone-formation
markers,
(5) 4 weeks of E treatment in the women (study A) led to
significant increases in bone-formation markers (P1NP and OCN)
and decreases in bone-resorption markers (CTX and TRACP5b).
As shown in Fig. 1, these changes were accompanied by
significant reductions in serum sclerostin levels using both the
in-house and commercial assays. Using data from both groups
combined, the percent change in serum sclerostin levels using
the in-house assay were significantly correlated with the percent
changes in serum sclerostin levels using the commercial assay
(r¼0.76, p<.0001). However, the percent changes in serum
P1NP or OCN levels did not correlate with percent changes in
sclerostin levels using either assay (r¼0.15, p¼.410, and r¼
–0.08, p¼.649 for P1NP and OCN, respectively, for the in-house
assay, and r¼–0.06, p¼.754, and r¼–0.10, p¼.563, for P1NP
and OCN, respectively, for the commercial assay). Of interest,
however, the percent change in serum CTX did correlate
significantly with changes in sclerostin levels using either the in-
house (Fig. 2A) or commercial assay (Fig. 2B), with similar
correlations for TRACP5b (Fig. 2C, D).
Table 3 also shows the changes in bone turnover markers in
the men (study B) following their hormonal manipulations. As
reportedpreviously
(8,10)withacutesexsteroiddeficiency(–T,–E),
serum P1NP levels decreased significantly in the men, and this
decrease was attenuated by E, but not by T, treatment.
Conversely, bone-resorption markers increased significantly
following sex steroid deficiency, and these increases were
Table 3. Percent Changes from Baseline in Bone Turnover Markers in the Study Subjects Following the Hormonal Manipulations
Study A: Women
Group Control E p Value
a
P1NP 12.2 6.4 42.1 9.3
    .012
OCN  2.0 2.7 6.6 2.8
  .034
CTX  7.5 5.2  36.8 3.0
    <.001
TRACP5b  2.6 2.1  25.3 2.2
    <.001
Study B: Men
Group –T, –E –T, þE þT, –E þT, þE
p Value
b
E effect T effect
P1NP  13.4 4.9
   8.3 2.3
    17.4 2.9
     3.7 2.9 .015 .486
CTX 56.3 14.3
   14.2 7.3 53.3 14.1
   10.2 7.9 <.001 .760
TRACP5b 16.7 2.4
    5.9 3.1 17.2 3.4
    2.6 1.5 <.001 .614
Note: For each group (eg, Men, –T, –E), the baseline values for each marker for that group, as shown in Table 2, were used to calculate percent changes.
 p<.05;
  p<.01;
   p<.001 versus baseline.
ap Value for comparison of the change in the E versus the control groups.
bp Value using a two-factor ANOVA model for E or T effects.
Table 2. Baseline Bone Turnover Markers and Sclerostin Levels in the Study Subjects
Study A: Women
Group Control E p Value
a
P1NP, mg/L 47.9 3.2 58.3 7.0 .174
OCN, ng/mL 29.8 2.2 28.8 2.1 .745
CTX, ng/mL 0.73 0.06 0.74 0.08 .936
TRACP5b, U/L 4.0 0.3 4.2 0.3 .716
Sclerostin (in-house assay), pg/mL 579 67 555 55 .782
Sclerostin (commercial assay), pg/mL 312 21 302 19 .731
Study B: Men
Group –T, –E –T, þE þT, –E þT, þE p Value
b
P1NP, mg/L 38.6 3.2 43.5 5.5 40.4 3.2 41.9 5.5 .880
CTX, ng/mL 0.54 0.05 0.55 0.8 0.50 0.05 0.54 0.07 .940
TRACP5b, U/L 3.8 0.3 2.9 0.2 3.4 0.3 3.1 0.3 .085
Sclerostin (commercial assay), pg/mL 439 33 446 44 406 29 447 47 .861
aFor comparison of control and estrogen groups.
bFor comparison of all four groups by ANOVA.
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and commercial sclerostin assays performed very similarly in the
women (Fig. 1), we only used the commercial assay in men, and
Fig. 3 shows the percent changes from baseline in serum
sclerostin levels in the four groups of men. As is evident, serum
sclerostin levels increased following sex steroid deficiency in the
–T, –E group; decreased significantly in the –T, þE group;
increasedsignificantly intheþT,–Egroup;anddidnotchangein
the sex steroid–sufficient group (þT, þE). Using the two-factor
ANOVA model, there was a highly significant E effect (p<.001)
on reducing sclerostin levels and a borderline significant
(p¼.052) T effect on increasing sclerostin levels, suggesting
opposite effects of E versus T on sclerostin levels. Similar to the
findings in the women, percent changes in serum P1NP levels in
the four groups combined did not correlate with changes in
sclerostin levels (r¼0.05, p¼.693). However, as in the women,
changes in serum CTX and in TRACP5b did correlate significantly
with changes in sclerostin levels (r¼0.33, p¼.009, and r¼0.32,
p¼.014, for CTX and TRACP5b, respectively).
Since previous studies have demonstrated that OPG is a Wnt
target gene,
(23) we tested whether the observed correlations
between changes in serum sclerostin levels and bone resorption
markers were accompanied by parallel changes in serum OPG
levels. Table 4 shows the baseline OPG levels in the subjects in
the two studies, as well as changes following the hormonal
manipulations.Asisevident,therewerenosignificantchangesin
serum OPG levels in any of the groups. Moreover, changes in
sclerostin levels did not correlate with changes in OPG levels
either in study A or study B (data not shown).
Discussion
Using two different study designs (E treatment versus E
withdrawal) and in both women and men, we demonstrate in
this study that E treatment reduces, whereas E withdrawal
increases, serum sclerostin levels. These data clearly establish
that circulating sclerostin levels and, presumably, sclerostin
production by osteocytes in bone are regulated by E. Our
findings are consistent with the recent observation by Mirza and
colleagues
(20) that serum sclerostin levels are inversely asso-
ciated with the free E2 index in postmenopausal women.
However, using direct interventions, our data provide proof of
Fig. 2. Correlations between percent changes in serum CTX in the two groups of women in study A combined versus percent change in serum sclerostin
levelsusingeitherthein-house(A)orcommercial(B)assay.PanelsCandDshowtheanalogousrelationshipsforTRACP5bversussclerostinusingeitherthe
in-house assay or commercial assay, respectively.
Fig. 1. Percent change from baseline in serum sclerostin levels in the
subjects in study A using either the in-house assay (open bars) or the
commercial assay (solid bars). p Values for differences in changes in
the control versus E-treated groups are as indicated.
   p<.001 for
significance of change from baseline.
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studies do not establish whether E regulates sclerostin
production directly or indirectly, Huang and colleagues
(24)
recently have identified a –9247 T/C polymorphism in the SOST
upstream regulatory regionthat is associated with spine, femoral
neck, trochanter, and totalhipbone mineral density (BMD)and is
located at the core consensus recognition site of two
cooperating transcription factors, C/EBPa and FOXA1, that
modulate E receptor (ER) function. Thus C/EBPa has been shown
to interact with ERa in glutathione-S-transferase pull-down
experiments,
(25) and knock-down of FOXA1 expression has been
shown to block the association of the ER with chromatin and
expression of E-induced genes.
(26,27) Moreover, the SOST
promoter has three additional classical E-response elements
between the –9247 polymorphism and the transcriptional start
site.
(24) As such, the SOST gene may be a direct target for E, but
clearly, further studies are needed to address whether E
regulates SOST expression at a transcriptional level.
In contrast to E, our data in study B indicate that T (in the
absence of aromatization to E) fails to suppress, and appears to
increase, circulatingsclerostin levels.WhileT previouslyhasbeen
thought of as being ‘‘anabolic’’ for bone, direct evidence for this
is relatively sparse.
(2) On the contrary, males with mutations
either in the ERa gene
(28,29) or in the gene encoding
aromatase
(30,31) have marked deficits in bone mass despite
having normal or elevated T levels. The biologic significance of
the apparent stimulatory effects of T on circulating sclerostin
levels, however, needs to be defined by additional studies in
humans and animal models.
In study A, we used two independent sclerostin assays to
evaluate changes following E treatment, with virtually identical
results. The fact that we got the same results using
independently generated antibodies to sclerostin (R&D Systems
and Biomedica) provides further confidence that our observa-
tionsarevalidindependentofthesclerostinantibodyusedinthe
assays. However, since the commercial assay is easier to perform
and has greater precision than our in-house assay, we used the
commercial assay in study B.
Perhaps somewhat surprising was our finding that changes in
sclerostin levels in both studies failed to correlate with changes
in bone-formation markers but did correlate with changes in
bone-resorption markers. The lack of correlation with the bone-
formationmarkerscouldbeduetoseveralreasons:First,changes
in sclerostin may account for only part of the effects of E in
maintaining bone formation, given the known multiple path-
ways regulated by E that could have an impact on bone
formation.
(2,32)Inaddition,itispossiblethatchangesinsclerostin
production occur well before changes in bone-formation
markers, and even sampling sclerostin levels 3 to 4 weeks
following E treatment or withdrawal may have missed more
robust changes in serum sclerostin levels early after changes in E
status, which also might have shown stronger associations with
the bone-formation markers. It is also possible that changes in
peripheral sclerostin levels may not fully reflect alterations in
sclerostin production in the bone microenvironment; however,
we have found recently
(33) that circulating sclerostin levels are
highly correlated with bone marrow plasma sclerostin levels,
Table 4. Baseline and Percent Changes in Serum OPG Levels in the Study Subjects Following the Hormonal Manipulations
Study A: Women
Group Control E p Value
a
OPG, pmol/L 3.4 0.4 3.0 0.3 .463
OPG, % change  1.6 4.5  6.7 5.0 .448
Study B: Men
Group –T, –E –T, þE þT, –E þT, þE p Value
b
OPG, pmol/L 2.9 0.2 2.9 0.2 2.6 0.1 2.8 0.3 0.624
E effect T effect
OPG, % change 3.8 3.5 1.6 5.3  2.8 3.3  2.1 3.7 .842 .207
Note: For each group, the percent changes were calculated using the respective baseline values.
 p<.05;
  p<.01;
   p<.001 versus baseline.
ap Value for comparison of baseline values or the percent change in the E versus the control groups.
bp Value for comparison of four groups at baseline by ANOVA or for E or T effects using a two-factor ANOVA model.
Fig. 3. Percent change from baseline in serum sclerostin levels in the
subjects in study B. The p values for the E and T effects are based on
the two-factor ANOVA model described under ‘‘Methods.’’ Briefly,
this compares changes in the þE versus –E groups for the E effect
and changes in the þT versus the –T groups for the T effect.
 p<.05,
  p<.01, and
yp¼.051 for significance of change from baseline.
32 Journal of Bone and Mineral Research MO ¨DDER ET AL.suggesting that peripheral sclerostin levels likely do accurately
reflect sclerostin levels in the bone microenvironment.
In contrast to the bone-formation markers, changes in
circulating sclerostin levels did correlate with changes in the
bone-resorption markers. These findings are consistent with a
recent study in rats showing that treatment of ovariectomized
rats with a neutralizing antibody to sclerostin not only increased
bone-formation rates but also reduced osteoclast numbers on
bone surfaces.
(19) Similarly, treatment of postmenopausal
women for up to 85 days with an antisclerostin antibody also
resulted in an increase in bone-formation markers as well as a
decrease in bone-resorption markers.
(34) These data in rats and
humans are entirely consistent with our findings, and increasing
evidence now indicates that changes in sclerostin activity
regulatenot only bone formation but also bone resorption. Since
OPG is a known Wnt target gene,
(23) we also tested whether the
association between changes in sclerostin levels and changes in
bone-resorption markers could be explained by alterations in
circulating OPG levels. However, this was not the case, and these
findings would suggest that mechanisms other than regulation
of OPG may account for the relationship between sclerostin
levelsandbone-resorptionmarkers,althoughwecannotexclude
the possibility that the lack of changes in serum OPG levels were
related to our relatively small sample size and/or the fact that
OPG is produced by a number of nonskeletal tissues.
(35) As such,
serum OPG levels may not reflect changes in the bone
microenvironment. Nonetheless, it is of interest that Wnt
signaling has been implicated recently in regulating not only
bone formation but also bone resorption. Thus activation of Wnt
signaling has been shown to downregulate RANKL mRNA and
protein expression in osteoblasts
(36) and to directly inhibit the
differentiation of osteoclast precursor cells through the
canonical pathway.
(37,38)
While our findings are consistent with E regulation of
sclerostin production in humans, we recognize that there is
currently no information on the stability of sclerostin or its
degradation in the circulation. Thus we cannot exclude an
effect of E on the metabolism of sclerostin; further studies
addressing this issue and, as noted earlier, examining possible
direct transcriptional regulation of the SOST gene by E need to
be done.
In summary, our studies demonstrate that in both sexes, E
decreases circulating sclerostin levels. While the reduction in
sclerostin production may play a role in the effects of E in
maintaining bone formation, the associations we observed
between changes in sclerostin levels and in bone-resorption
markers suggest that at least part of the antiresorptive effects of
Ealsomaybemediatedviachangesinsclerostinproduction. Our
findings thus identify sclerostin as a potentially important
mediator of E effects on bone turnover, and further human and
animal studies are needed to more precisely define how much of
the overall E effect on bone formation and resorption can be
explained by changes in sclerostin production.
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